Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Clin Virol ; 36(1): 24-31, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16483838

RESUMO

BACKGROUND: The outcome of acute hepatitis C is determined by early host-virus interactions, particularly involving the antiviral T-cell response. OBJECTIVES: To identify early prognostic markers of spontaneous resolution of acute hepatitis C by performing a comprehensive analysis of viral and immunological factors during the natural course of acute HCV infection and reinfection. STUDY DESIGN: 20 patients were investigated prospectively during acute HC or confirmed reinfection and 18 of them during follow up after spontaneous or treatment-induced elimination of the virus and resolution of the disease. Multiparameter flow cytometry was used to functionally characterize virus-specific CD4(+) T-cell responses relative to the virologic outcome. RESULTS: Parallel immunologic and virologic monitoring of patients with acute HC identified distinct patterns of host-virus interaction related to HCV persistence or clearance. The highest frequency of antiviral Th1 cytokine-producing CD4(+) T-cells was observed in patients with HCV reinfection, preceding rapid viral clearance within 3 weeks after disease onset. In all patients who subsequently cleared viremia, CD4(+) T-cells produced Th1 cytokines following stimulation with non-structural HCV antigens (NS3 and NS4). In contrast, a chronic course of disease was associated with the absence of antiviral Th1 cytokine producing cells from the first weeks after onset of disease (acute persistent HC), or with fluctuating RNA levels (yo-yo pattern) and gradual waning of antiviral Th1 cells. CONCLUSIONS: The results highlight the variability of immune response pattern in acute hepatitis C. Most importantly, "acute persistent hepatitis C" and a lack of TH1 effector cells within the first months of acute hepatitis C represent efficacious predictors of viral persistence and could thus be used as criteria in selecting candidates for early antiviral treatment.


Assuntos
Linfócitos T CD4-Positivos/imunologia , Hepacivirus/isolamento & purificação , Hepatite C/imunologia , Hepatite C/virologia , RNA Viral/análise , Adolescente , Adulto , Contagem de Linfócito CD4 , Estudos de Coortes , Feminino , Citometria de Fluxo , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Prospectivos , Design de Software , Carga Viral , Viremia
2.
J Infect Dis ; 195(9): 1315-9, 2007 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-17397001

RESUMO

T cell immune responses may be important for the elimination of chronic hepatitis C virus (HCV) infection during antiviral treatment. In the present study, the kinetics of T cell responses to HCV antigens (NS3-4 and core) were prospectively assessed and were correlated with virologic outcome in 31 patients with chronic HCV infection undergoing peginterferon- alpha 2a/ribavirin therapy. NS3-4--directed T helper cell type 1 (Th1) responses were detected in 77% of patients with a significant decline in viremia at treatment week 4 but were not detected not in those with a slower viral decline. The detectability of NS3-4--directed Th1 responses was associated with faster viremia clearance, was short-lived, and did not seem to be associated with the final treatment outcome.


Assuntos
Antivirais/uso terapêutico , Linfócitos T CD4-Positivos/imunologia , Hepacivirus/imunologia , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/imunologia , Interferon-alfa/uso terapêutico , Polietilenoglicóis/uso terapêutico , Ribavirina/uso terapêutico , Adulto , Antígenos Virais/imunologia , Antivirais/administração & dosagem , Quimioterapia Combinada , Feminino , Hepatite C Crônica/sangue , Humanos , Interferon alfa-2 , Interferon-alfa/administração & dosagem , Masculino , Pessoa de Meia-Idade , Polietilenoglicóis/administração & dosagem , RNA Viral/análise , Proteínas Recombinantes , Ribavirina/administração & dosagem , Resultado do Tratamento , Carga Viral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA